

Please amend claims 1, 3-5, 14 as follows:

C1 1. (Amended) An isolated nucleic acid molecule comprising any one of SEQ ID NOs: 1, 4-5, 7, 9, 11 or 13, or a fragment of any one of SEQ ID NOs: 1, 4-5, 7, 9, 11 or 13, wherein said fragment encodes a polypeptide having at least one biological activity of an OGF receptor (OGFr).

3. (Amended) An isolated nucleic acid molecule, the complement sequence of which hybridizes under stringent conditions to any of SEQ ID NOs: 1, 4-5, 7, 9, 11 and 13, wherein said nucleic acid molecule encodes an OGFr, and wherein said stringent conditions comprise hybridization at about 65°X and washing in about 0.1X-2x SSC with about 0.1% SDS.

C2 4. (Amended) An isolated nucleic acid molecule comprising an antisense sequence of any one of SEQ ID NOs: 1, 4-5, 7, 9, 11 or 13.

5. (Amended) An expression vector comprising any one of the isolated nucleic acid molecules of claims 1, 3-4 or 38-39.

C3 14. (Amended) A pharmaceutical composition comprising the isolated nucleic acid molecule of any one of claims 1, 3 or 38-39 and a pharmaceutically acceptable carrier.

Claims 38-39 have been added:

38. An isolated nucleic acid molecule encoding a protein wherein said protein has a sequence as set forth in any one of SEQ ID NOS: 2, 6, 8, 10, 12 or 14.

C4 39. An isolated nucleic acid molecule encoding a protein wherein said protein is an OGF receptor and has a sequence which bears at least about 75% similarity to any one of SEQ ID NOS: 2, 6, 8, 10, 12 or 14.